Startup Pardes Biosciences Inc. has begun clinical trials of a pill for Covid-19, entering the hunt for an oral medicine that could be widely used to treat and prevent the disease.
U.S. regulators have approved the drug remdesivir, made by Gilead Sciences Inc., for hospitalized patients, and monoclonal antibodies taken intravenously have gained emergency-use authorizations to treat patients at high risk for developing severe Covid-19 and to prevent hospitalizations.
Carlsbad,…
This post first appeared on wsj.com
